I received my Ph.D. in 2013, advised by S. Walter Englander at the University of Pennsylvania, Perelman School of Medicine in Biochemistry and Molecular Biophysics studying the basic kinetic mechanisms of protein folding reactions. I joined Genentech as a post-doc in the protein analytical chemistry (PAC-2) and early-stage formulations departments (ESPD) in 2013 with Jennifer Zhang and Tom Patapoff. I have moved around throughout the company working on problems that involve protein dynamics ever since. My lab relies heavily on hydrogen-deuterium exchange experiments along and molecular dynamics simulations. I am currently a senior principal scientist in gRED Drug Discovery, jointly appointed to the departments of Structural Biology and Biochemistry and Cellular Pharmacology. I am also the current chair of the International Society for Hydrogen Deuterium Exchange since 2022.
Working as a post-doc mentor at Genentech has been a gratifying experience. I've had the opportunity to learn from vibrant and intelligent individuals at the onset of their careers. Together, we leverage the extensive array of tools available to Genentech researchers and tap into our vast data repositories to tackle intriguing biophysics problems.
During my tenure as a post-doc at Genentech (2013-2015), I learned how to cultivate a research program in a highly collaborative environment that fostered my development as a scientist. I built rewarding collaborations across the company because of the culture at Genentech. Everyone openly shares their time and resources to help our post-docs succeed. Having the opportunity mentor someone else while working together on engaging research problems has been a highlight of my career.
Cell Chem Biol. 2023
J Pharm Sci. 2022
Multiscale Coarse-Grained Approach to Investigate Self-Association of Antibodies.
Biophys J. 2020
An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.
Anal. Chem. 2017, 89, 2, 1049–1053
HX measurements also serve as a guide or driver for our MD simulations. The group focuses on new ways to simulate macromolecules to determine a variety of data, such as how small molecules bind to their targets, protein-protein interactions, and even their visco-elastic properties. This unique research area sits at the intersection of computational and experimental sciences, positioning our team in a rewarding and innovative space. Presently, we work primarily in the hit-to-lead phase of drug discovery but over the last ten years at Genentech, I have utilized these tools to solve protein dynamics problems throughout discovery and development. See my publications for more examples.